Science Current Events | Science News | Brightsurf.com
 

Anti-HIV drug use during pregnancy does not affect infant size, birth weight

May 03, 2012

NIH study indicates drug safe during pregnancy, but infants smaller at first birthday

Infants born to women who used the anti-HIV drug tenofovir as part of an anti-HIV drug regimen during pregnancy do not weigh less at birth and are not of shorter length than infants born to women who used anti-HIV drug regimens that do not include tenofovir during pregnancy, according to findings from a National Institutes of Health network study. However, at 1 year of age, children born to the tenofovir-treated mothers were slightly shorter and had slightly smaller head circumference-about 1 centimeter each, on average-than were infants whose mothers did not take tenofovir.

The study authors described the findings as reassuring, noting that the study did not identify any serious safety concerns during pregnancy for tenofovir. In combination with other anti-HIV drugs, tenofovir is the first line of treatment for adults with HIV. The researchers called for additional studies to follow the children as they grow and develop, to identify any potential long term effects of the treatment. Information on Tenofovir and formulations containing tenofovir is available at http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0000198/.

The study was undertaken because earlier studies had shown laboratory animals exposed to tenofovir in the womb were smaller at birth than were their unexposed peers.

Because of its safety and effectiveness, many women who have HIV take the drug for their health, often before they become pregnant. Similarly, because the drug is so effective for adult use and because there have been no problems reported in human infants related to their mother's use of tenofovir, many physicians will prescribe it for pregnant women, both to safeguard the women's health and to prevent the virus from being passed on to their infants. However, before the current research, the drug had not been specifically studied for its potential effects on infants whose mothers took it during pregnancy.

"Physicians treating pregnant women for HIV face a dilemma: do they continue treating a pregnant woman with a drug that is highly effective for adults but which has not been studied for its effects on infants, or do they switch the woman to another therapy, which may not be as effective and well-tolerated?" said first author George K. Siberry, M.D., of the Pediatric, Adolescent and Maternal AIDS Branch of the NIH's Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the NIH institute that conducted the study. "Our findings indicate that tenofovir does not affect the growth of the fetus."

Over the seven years of the study, the number of participants being treated with tenofovir increased sharply, the study authors noted. In 2003, 14 percent of mothers in the study had been prescribed the drug, compared with 43 percent in 2010.

"The priority has been to treat mothers and prevent an infant's infection," said co-author Paige L. Williams, Ph.D., of the Harvard School of Public Health, Boston. "However, it's important to monitor the effects of these drugs on the infant."

The research was conducted as part of the Pediatric HIV/AIDS Cohort Study (PHACS), which is supported by the NICHD, the National Institute of Allergy and Infectious Diseases, the National Institute on Drug Abuse, the National Institute of Mental Health, the National Institute on Deafness and other Communication Disorders, the National Heart, Lung, and Blood Institute, the National Institute of Neurological Disorders and Stroke, and the National Institute on Alcohol Abuse and Alcoholism.

Dr. Siberry and Dr. Williams collaborated with colleagues at the State University of New York Downstate, Brooklyn; University of Miami School of Medicine; Indiana University School of Medicine, Indianapolis; Harvard; and the NICHD.

Their findings appear online in the journal AIDS.

The study included 2,000 U.S. infants born to HIV-positive mothers between 2003 and 2010. The researchers collected data for the infants' size relative to their gestational age (time they had spent in the womb), their birth weight, length at birth, and the circumference of their head. The researchers recorded similar measurements when the child was 1 year old.

They found that mothers taking tenofovir in combination with other anti-HIV medications and mothers on anti-HIV drug combinations that did not include tenofovir gave birth to infants who were smaller, on average, than infants born to HIV-negative mothers. However, they did not find significant differences between infants from the two groups of HIV-positive mothers.

The tenofovir-exposed infant's smaller average size and head circumference at one year of age suggests tenofovir could have a delayed effect on growth. Further research on this and other classes of anti-HIV drugs is ongoing in the PHACS.

"Overall, this study produced reassuring information regarding the use of tenofovir," said Dr. Siberry. "Although further research is needed, on balance, our findings favor the use of tenofovir in pregnancy to ensure good outcomes in the mother and prevent transmission of HIV to the infant."

NIH/National Institute of Child Health and Human Development


Related Tenofovir Current Events and Tenofovir News Articles


Studies demonstrate improved safety results achieved with investigational drug for hep B
Studies presented today at The International Liver Congress™ 2016 in Barcelona, Spain, demonstrate that tenofovir alafenamide (TAF) improves patient safety while maintaining efficacy in patients with chronic Hepatitis B virus (HBV) infection compared to tenofovir disoproxil fumarate (Viread, TDF).

Maraviroc-containing regimens safe, tolerable when taken for HIV prevention
Maraviroc, an oral drug used to treat HIV infection, is safe and well-tolerated when taken daily as pre-exposure prophylaxis (PrEP) to prevent HIV infection by HIV-uninfected men who have sex with men (MSM) at increased risk for acquiring HIV.

One drug used to prevent HIV transmission during pregnancy shows evidence of developmental effects
The antiretroviral (ARV) drug atazanavir--sometimes included in treatments to prevent mother-to-child HIV transmission during pregnancy--may have small but significant effects on infant development, reports a study in the journal AIDS, official journal of the International AIDS Society. AIDS is published by Wolters Kluwer.

Progress toward an HIV cure highlighted in special issue of AIDS Research and Human Retroviruses
A cure for HIV/AIDS is the ultimate goal of rapidly advancing research involving diverse and innovative approaches.

Population Council's MZC outperforms TFV 1 percent gel in microbicide candidate preclinical study
New data from a preclinical safety and efficacy study of the candidate microbicide gel MZC, which targets HIV, herpes simplex virus (HSV-2) and human papillomavirus (HPV), shows that the gel performs as well as, or in many cases, better than, tenofovir (TFV) 1% gel, a leading microbicide candidate.

Effect of pre-exposure prophylaxis for HIV infection integrated with community health services
The rate of acquiring human immunodeficiency virus (HIV) was extremely low despite a high incidence of sexually transmitted infections (STIs) in a study where pre-exposure antiretroviral medication to prevent HIV infection was dispensed at clinics in three metropolitan areas heavily affected by HIV, according to an article published online by JAMA Internal Medicine.

Silicone vaginal rings deliver antiviral drugs, protect women against HIV
Researchers at University Jean Monnet of Saint-Etienne, France have succeeded in developing a vaginal silicone ring that delivers molecules that act on both HIV and herpes virus. This research is presented at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC/ICC).

Stopping HIV in its tracks
Is the end of HIV near? Findings published this week in Antimicrobial Agents and Chemotherapy report that a novel, subdermal implant delivering potent antiretroviral (ARV) drugs shows extreme promise in stopping the spread of HIV.

Long-term therapy with ETV or TDF demonstrates positive 5-year survival in patients with chronic HBV
Data revealed today at The International Liver Congress™ 2015 show that the long-term use of entecavir (ETV) or tenofovir (TDF) results in excellent 5-year survival for Caucasian patients with chronic hepatitis B (CHB), with more than 95% of patients surviving at 5 years and a significant proportion of deaths coming from liver-unrelated causes.

Providers have mixed feelings about prescribing HIV prevention
Many health care providers across the United States may be reluctant to prescribe an increasingly important prevention approach to some of their patients who are at substantial ongoing risk for HIV.
More Tenofovir Current Events and Tenofovir News Articles

Degradation Study Of Tenofovir Disoproxil Fumarate: RP-HPLC Method Development

Degradation Study Of Tenofovir Disoproxil Fumarate: RP-HPLC Method Development
by Shubhangi Sutar (Author), Shitalkumar Patil (Author), Sachin Pishavikar (Author)


Stability indicating RP-HPLC method for estimation of Tenofovir Disoproxil Fumarate in the presence of its degradation products during conduction of stability studies on the pure drug which was carried out by using a mobile phase comprising ACN: Water (70:30 v/v), pH adjusted to 4.5with OPA,, at flow rate of 1 ml/min. with UV detection at 260 nm. The concentration of TDF was found sufficient for obeying Beer’s law over a range of 10-90μg/ml. In the present study, the drug was subjected to acid (0.1N HCl and 0.01N HCl), and alkaline (0.1N NaOH and 0.01N NaOH) hydrolysis. TDF was found to be more sensitive to alkaline hydrolysis and it was somewhat stable to acidic conditions. The degradation kinetic of Tenofovir Disoproxil Fumarate is governed by hydrolysis of the...

Tenofovir: Webster's Timeline History, 2000 - 2007

Tenofovir: Webster's Timeline History, 2000 - 2007
by Icon Group International (Author)


Webster's bibliographic and event-based timelines are comprehensive in scope, covering virtually all topics, geographic locations and people. They do so from a linguistic point of view, and in the case of this book, the focus is on "Tenofovir," including when used in literature (e.g. all authors that might have Tenofovir in their name). As such, this book represents the largest compilation of timeline events associated with Tenofovir when it is used in proper noun form. Webster's timelines cover bibliographic citations, patented inventions, as well as non-conventional and alternative meanings which capture ambiguities in usage. These furthermore cover all parts of speech (possessive, institutional usage, geographic usage) and contexts, including pop culture, the arts, social sciences...

Antibiotics Simplified

Antibiotics Simplified
by Jason C. Gallagher (Author), Conan MacDougall (Author)


Antibiotics Simplified is included in the 2015 edition of the essential collection of Doody’s Core Titles. Antibiotics Simplified, Third Edition is a best-selling, succinct guide designed to bridge knowledge gained in basic sciences courses with clinical practice in infectious diseases. This practical text reviews basic microbiology and how to approach the pharmacotherapy of a patient with a presumed infection. It also contains concise Drug Class Reviews with an explanation of the characteristics of various classes of antibacterial drugs and antifungal drugs. Antibiotics Simplified, Third Edition simplifies learning infectious disease pharmacotherapy and condenses the many facts that are taught about antibiotics into one quick reference guide. This guide will help students learn the...

Memorizing Pharmacology: A Relaxed Approach

Memorizing Pharmacology: A Relaxed Approach
by Tony Guerra (Author)


As a working parent of 4yearold triplet daughters, I understand time management presents one of the greatest barriers to my pharmacology students' success. Many students feel that cold sense of overwhelm and information overload. This easytoread guide organizes pharmacology into manageable, logical steps you can fit in short pockets of time. The proven system helps you memorize medications quickly and form immediate connections. With mnemonics from students and instructors, you'll see how both sides approach learning. After you've finished the 200 Top Drugs in this book, reading pharmacology exam questions will seem like reading plain English. You'll have a new understanding of pharmacology to do better in class, clinical and your board exam. You'll feel the confidence you'd hoped for as...

Clinical Challenges in Therapeutic Drug Monitoring: Special Populations, Physiological Conditions and Pharmacogenomics

Clinical Challenges in Therapeutic Drug Monitoring: Special Populations, Physiological Conditions and Pharmacogenomics
by William Clarke PhD MBA (Editor), Amitava Dasgupta (Editor)


Clinical Challenges in Therapeutic Drug Monitoring: Special Populations, Physiological Conditions and Pharmacogenomics focuses on critical issues in therapeutic drug monitoring including special requirements of therapeutic drug monitoring important to special populations (infants and children, pregnant women, elderly patients, and obese patients). The book also covers issues of free drug monitoring and common interferences in using immunoassays for therapeutic drug monitoring. This book is essential reading for any clinician, fellow, or trainee who wants to gain greater insight into the process of therapeutic drug monitoring for individual dosage adjustment and avoiding drug toxicity for certain drugs within a narrow therapeutic window. The book is written specifically for busy...

TRUVADA Tablet: Used with other Medicines for the Treatment of the Infection Caused by the Human Immunodeficiency Virus (HIV)

TRUVADA Tablet: Used with other Medicines for the Treatment of the Infection Caused by the Human Immunodeficiency Virus (HIV)
by James Lee Anderson (Author)


“Although, your health condition may impact your everyday life, do not let it define who you are.” TRUVADA (containing emtricitabine and tenofovir disoproxil fumarate) is used along with other medications to treat HIV in patients who are 12 years of age and older. It is also used along with practicing safer sex to help prevent patients, who are at high risk, from getting HIV. Emtricitabine and tenofovir are in a class of medications called nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs). They work by slowing the spread of HIV in the body. Although TRUVADA will not cure HIV, this medication may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. Taking this medication along...

TRUVADA Tablet: Used with other Medicines for the Treatment of the Infection Caused by Human Immunodeficiency Virus (HIV)

TRUVADA Tablet: Used with other Medicines for the Treatment of the Infection Caused by Human Immunodeficiency Virus (HIV)


“Although, your health condition may impact your everyday life, do not let it define who you are.”

TRUVADA (containing emtricitabine and tenofovir disoproxil fumarate) is used along with other medications to treat HIV in patients who are 12 years of age and older. It is also used along with practicing safer sex to help prevent patients, who are at high risk, from getting HIV. Emtricitabine and tenofovir are in a class of medications called nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs). They work by slowing the spread of HIV in the body. Although TRUVADA will not cure HIV, this medication may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. Taking this...

PASS-NAPLEX Course Book Volume II: A Comprehensive Course for the NAPLEX and CPJE (2016 Edition)

PASS-NAPLEX Course Book Volume II: A Comprehensive Course for the NAPLEX and CPJE (2016 Edition)
by Tuan Nguyen (Author)


LESS is MORE!! The PASS-NAPLEX course books are the ONLY SIMPLIFIED study guide for pharmacy graduates preparing for the North American Pharmacist Licensure Examination. The content of the books is the product of NAPLEX Blueprint ONLY. Keep this in mind, this is an entry level cumulative test. The books are the Cliffs Notes or Simplified Notes for the exam. There are two volumes to the course. The volume one contains 38 topics, one of which focuses on the cardiovascular topic. The volume two contains 21 topics, one of which focuses on the anti-infective topic. For each topic, it is separated into three sections. The first section shows the correlation between the drug mechanism of action to its adverse side effects and patient consultation. The second section groups all drugs dosage...

The Harriet Lane Handbook of Pediatric Antimicrobial Therapy: Mobile Medicine Series (Expert Consult: Online + Print), 2e

The Harriet Lane Handbook of Pediatric Antimicrobial Therapy: Mobile Medicine Series (Expert Consult: Online + Print), 2e
by Julia McMillan MD (Author), Carlton K. Lee PharmD MPH (Author), George K. Siberry MD MHP (Author), Karen Carroll MD (Author)


From the experts at Johns Hopkins University who bring you the bestselling Harriet Lane Handbook, the Harriet Lane Handbook of Pediatric Antimicrobial Therapy delivers quick, dependable answers to help you effectively treat a broad spectrum of pediatric infectious diseases. This highly regarded medical reference book is your pocket-sized source for all of the evidence-based recommendations you need to provide the best possible care to your young patients. Get all of the information you need to prescribe the correct drug and the appropriate dose through a detailed drug formulary, expanded from the popular Harriet Lane Handbook.Better manage persistent, hard-to-fight pediatric infections with a section on adverse effects and drug resistance.Make the best clinical decisions with up-to-date...

HIV Essentials 2014

HIV Essentials 2014
by Paul E. Sax (Author), Calvin J. Cohen (Author), Daniel R. Kuritzkes (Author)


The world's leading experts provide all the 'essentials' needed to manage HIV patients in the office, on the ward, and in the ICU. Completely revised and updated, HIV Essentials 2014 incorporates the latest clinical guidelines into a step-by-step guide to the diagnosis, evaluation, management, and prevention of HIV infection and its complications. Topics include: opportunistic infections and other HIV complications, treatment of HIV and pregnancy, antiretroviral drug summaries, post-exposure prophylaxis, as well as commercially available dosage forms for all ARVs.

© 2016 BrightSurf.com